Download PDF
Indian Journal of Neurosurgery 2013; 02(02): 131-137
DOI: 10.4103/2277-9167.118112
Review Article
Thieme Medical and Scientific Publishers Private Ltd.

Evolution of radiotherapy and chemotherapy practice in malignant gliomas

Anusheel Munshi
,
Sayan Paul
Subject Editor:
Further Information

Publication History

Publication Date:
18 January 2017 (online)

  PDF Download  Permissions and Reprints

Abstract

Malignant astrocytomas of the brain carry a poor prognosis. This article traces the evolution of radiotherapy and chemotherapy practice including the development of concurrent chemo-radiation schedules in the context of these tumors.

Key words

Chemotherapy - glioma - radiotherapy
 

  • References

  • 1 Davis FG, Preston-Martin S, Bigner DD, McLendon RE, Bruner JM. Epiodemiology, incidence and survival. Russell and Rubinstein’s Pathology of Tumors of Central Nervous System. Publisher location: Boca Raton, FL 33487-2742: Arnold; 1999. p 7
    Google Scholar
  • 2 Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin 1999; 49: 8-31 1
    CrossrefPubMedGoogle Scholar
  • 3 Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C. et al Cancer statistics, 2006. CA Cancer J Clin 2006; 56: 106-130
    CrossrefPubMedGoogle Scholar
  • 4 Schwartzbaum JA, Fisher JL, Aldape KD, Wrensch M. Epidemiology and molecular pathology of glioma. Nat Clin Pract Neurol 2006; 2: 494-503
    PubMedGoogle Scholar
  • 5 Radhakrishnan K, Mokri B, Parisi JE, O’Fallon WM, Sunku J, Kurland LT. The trends in incidence of primary brain tumors in the population of Rochester, Minnesota. Ann Neurol 1995; 37: 67-73
    CrossrefPubMedGoogle Scholar
  • 6 Hart MG, Garside R, Rogers G, Stein K, Grant R. Temozolomide for high grade glioma. Cochrane Database Syst Rev 2013; 4: CD007415
    PubMedGoogle Scholar
  • 7 Tseng JH, Merchant E, Tseng MY. Effects of socioeconomic and geographic variations on survival for adult glioma in England and Wales. Surg Neurol 2006; 66: 258-263
    CrossrefPubMedGoogle Scholar
  • 8 Kleihues P, Cavenee WK. editors Pathology and genetics of tumours of thenervous system. World Health Organization Classification of Tumours. Lyon, France: IARC Press; 2000
    Google Scholar
  • 9 Watanabe K, Tachibana O, Sata K, Yonekawa Y, Kleihues P, Ohgaki H. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 1996; 6: 217-223
    CrossrefPubMedGoogle Scholar
  • 10 Biernat W, Tohma Y, Yonekawa Y, Kleihues P, Ohgaki H. Alterations of cell cycle regulatory genes in primary (de novo) and secondary glioblastomas. Acta Neuropathol 1997; 94: 303-309
    CrossrefPubMedGoogle Scholar
  • 11 Tohma Y, Gratas C, Biernat W, Peraud A, Fukuda M, Yonekawa Y. et al PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas. J Neuropathol Exp Neurol 1998; 57: 684-689
    CrossrefPubMedGoogle Scholar
  • 12 Hermanson M, Funa K, Koopmann J, Maintz D, Waha A, Westermark B. et al Association of loss of heterozygosity on chromosome 17p with high platelet-derived growth factor alpha receptor expression in human malignant gliomas. Cancer Res 1996; 56: 164-171
    PubMedGoogle Scholar
  • 13 Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J. et al Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: Long-term results of RTOG 9402. J Clin Oncol 2013; 31: 337-343
    CrossrefPubMedGoogle Scholar
  • 14 Yano S, Kuratsu J. Kumamoto Brain Tumor Research Group. Indications for surgery in patients with asymptomatic meningiomas based on an extensive experience. J Neurosurg 2006; 105: 538-543
    CrossrefPubMedGoogle Scholar
  • 15 Laws ER, Parney IF, Huang W, Anderson F, Morris AM, Asher A. et al Survival following surgery and prognostic factors for recently diagnosed malignant glioma: Data from the Glioma Outcomes Project. J Neurosurg 2003; 99: 467-473
    CrossrefPubMedGoogle Scholar
  • 16 Cloughesy T, Selch MT, Liau L. Brain. In: Haskell CM. editor Cancer Treatment. 5th ed Philadelphia, PA: WB Saunders Co; 2001. p 1106-1142
    Google Scholar
  • 17 Walker MD, Alexander Jr E, Hunt WE, MacCarty CS, Mahaley Jr MS, Mealey Jr J. et al Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 1978; 49: 333-343
    CrossrefPubMedGoogle Scholar
  • 18 Bleehen NM, Stenning SP. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party. Br J Cancer 1991; 64: 769-774
    CrossrefPubMedGoogle Scholar
  • 19 Laperriere N, Zuraw L, Cairncross G. Cancer Care Ontario Practice Guidelines Initiative Neuro-Oncology Disease Site Group. Radiotherapy for newly diagnosed malignant glioma in adults: A systematic review. Radiother Oncol 2002; 64: 259-273
    CrossrefPubMedGoogle Scholar
  • 20 Tsao MN, Mehta MP, Whelan TJ, Morris DE, Hayman JA, Flickinger JC. et al The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for malignant glioma. Int J Radiat Oncol Biol Phys 2005; 63: 47-55
    CrossrefPubMedGoogle Scholar
  • 21 Souhami L, Seiferheld W, Brachman D, Podgorsak EB, Werner-Wasik M, Lustig R. et al Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: Report of Radiation Therapy Oncology Group 93-05 protocol. Int J Radiat Oncol Biol Phys 2004; 60: 853-860
    CrossrefPubMedGoogle Scholar
  • 22 Laperriere NJ, Leung PM, McKenzie S, Milosevic M, Wong S, Glen J. et al Randomized study of brachytherapy in the initial management of patients with malignant astrocytoma. Int J Radiat Oncol Biol Phys 1998; 41: 1005-1011
    CrossrefPubMedGoogle Scholar
  • 23 Fiveash JB, Spencer SA. Role of radiation therapy and radiosurgery in glioblastoma multiforme. Cancer J 2003; 9: 222-229
    CrossrefPubMedGoogle Scholar
  • 24 Walker MD, Green SB, Byar DP, Alexander Jr E, Batzdorf U, Brooks WH. et al Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 1980; 303: 1323-1329
    CrossrefPubMedGoogle Scholar
  • 25 Stewart LA. Chemotherapy in adult high-grade glioma: A systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002; 359: 1011-1018
    CrossrefPubMedGoogle Scholar
  • 26 Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ. et al Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-996
    CrossrefPubMedGoogle Scholar
  • 27 Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC. et al Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10: 459-466
    CrossrefPubMedGoogle Scholar
  • 28 Stupp R, Hottinger AF, van den Bent MJ, Dietrich PY, Brandes AA. Frequently asked questions in the medical management of high-grade glioma: A short guide with practical answers. Ann Oncol 2008; 19 (Suppl. 07) vii 209-216
    PubMedGoogle Scholar
  • 29 Yamamoto H, Sato F, Nakamura O, Kohno T, Shitara N, Takakura K. et al Synchronization chemoradiotherapy for malignant gliomas. No Shinkei Geka 1984; 12: 795-780
    PubMedGoogle Scholar
  • 30 Sandberg-Wollheim M, Malmström P, Strömblad LG, Anderson H, Borgström S, Brun A. et al A randomized study of chemotherapy with procarbazine, vincristine, and lomustine with and without radiation therapy for astrocytoma grades 3 and/or 4. Cancer 1991; 68: 22-29
    CrossrefPubMedGoogle Scholar
  • 31 Fine HA, Dear KB, Loeffler JS, Black PM, Canellos GP. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 1993; 71: 2585-2597
    CrossrefPubMedGoogle Scholar
  • 32 Krishnasamy S, Vokes EE, Dohrmann GJ, Mick R, Garcia JC, Kolker JD. et al Concomitant chemoradiotherapy, neutron boost, and adjuvant chemotherapy for anaplastic astrocytoma and glioblastoma multiforme. Cancer Invest 1995; 13: 453-459
    CrossrefPubMedGoogle Scholar
  • 33 van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJ, Bernsen HJ. et al Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: A randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 2006; 24: 2715-2722
    CrossrefPubMedGoogle Scholar
  • 34 Shibui S, Narita Y, Mizusawa J, Beppu T, Ogasawara K, Sawamura Y. et al Randomized trial of chemoradiotherapy and adjuvant chemotherapy with nimustine (ACNU) versus nimustine plus procarbazine for newly diagnosed anaplastic astrocytoma and glioblastoma (JCOG0305). Cancer Chemother Pharmacol 2013; 71: 511-521
    CrossrefPubMedGoogle Scholar
  • 35 Friedman GK, Spiller SE, Harrison DK, Fiveash JB, Reddy AT. Treatment of children with glioblastoma with conformal radiation, temozolomide and bevacizumab as adjuncts to surgical resection. J Pediatr Hematol Oncol 2013; 35: e123-e126
    CrossrefPubMedGoogle Scholar
  • 36 van den Bent MJ, Brandes AA, Taphoorn MJ, Kros JM, Kouwenhoven MC, Delattre JY. et al Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: Long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 2013; 31: 344-350
    CrossrefPubMedGoogle Scholar
  • 37 McNamara MG, Sahebjam S, Mason WP. Anaplastic oligodendroglioma: Advances and treatment options. Curr Treat Options Neurol 2013; 15: 289-301
    CrossrefPubMedGoogle Scholar
  • 38 Cage TA, Clark AJ, Aranda D, Gupta N, Sun PP, Parsa AT. et al A systematic review of treatment outcomes in pediatric patients with intracranial ependymomas. J Neurosurg Pediatr 2013; 11: 673-681
    CrossrefPubMedGoogle Scholar
  • 39 Valtonen S, Timonen U, Toivanen P, Kalimo H, Kivipelto L, Heiskanen O. et al Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: A randomized double-blind study. Neurosurgery 1997; 41: 44-48
    CrossrefPubMedGoogle Scholar
  • 40 Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Warnke PC. et al A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol 2003; 5: 79-88
    CrossrefPubMedGoogle Scholar
  • 41 Westphal M, Ram Z, Riddle V, Hilt D, Bortey E. Executive Committee of the Gliadel Study Group. Gliadel wafer in initial surgery for malignant glioma: Long-term follow-up of a multicenter controlled trial. Acta Neurochir (Wien) 2006; 148: 269-275
    CrossrefPubMedGoogle Scholar
  • 42 Hart MG, Grant R, Garside R, Rogers G, Somerville M, Stein K. Chemotherapeutic wafers for High Grade Glioma. Cochrane Database Syst Rev 2008; 3: CD007294
    PubMedGoogle Scholar
  • 43 Koshy M, Villano JL, Dolecek TA, Howard A, Mahmood U, Chmura SJ. etal Improved survival time trends for glioblastoma using the SEER 17 population-based registries. J Neurooncol 2012; 107: 207-212
    CrossrefPubMedGoogle Scholar
  • 44 Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F. et al A multivariate analysis of 416 patients with glioblastoma multiforme: Prognosis, extent of resection, and survival. J Neurosurg 2001; 95: 190-198
    CrossrefPubMedGoogle Scholar
  • 45 Malmstrom A, Grønberg BH, Marosi C, Stupp R, Frappaz D, Schultz H. et al Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: The Nordic randomised, phase 3 trial. Lancet Oncol 2012; 13: 916-926
    CrossrefPubMedGoogle Scholar
  • 46 Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M. et al Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: The NOA-08 randomised, phase 3 trial. Lancet Oncol 2012; 13: 707-715
    CrossrefPubMedGoogle Scholar
  • 47 Dai XJ, Jiang WJ, Wang WM, Zhao SJ. Drug or vaccine?: Selecting the appropriate treatment for malignant glioma patients. Drugs 2010; 70: 1477-1486
    CrossrefPubMedGoogle Scholar
  • 48 Hernandez-Pedro NY, Rangel-Lopez E, Magana-Maldonado R, de la Cruz VP, Santamaria Del Angel A, Pineda B. et al Application of nanoparticles on diagnosis and therapy in gliomas. Biomed Res Int 2013; 2013: 351031
    PubMedGoogle Scholar
  • 49 Munshi A. Chloroquine in glioblastoma - New horizons for an old drug. Cancer 2009; 115: 2380-2383
    CrossrefPubMedGoogle Scholar